Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hi-Tech Pharmacal, a specialty pharma company developing, manufacturing and marketing generic, branded prescription and OTC products, has acquired the marketing and distribution rights of a topical product - Hylase Wound Gel - from Glycobiosciences.
Subscribe to our email newsletter
Hylase Wound Gel is indicated for the management and treatment of leg ulcers, pressure ulcers, diabetic ulcers and exuding wounds prone to bleeding.
ECR Pharmaceuticals, Hi-Tech’s branded subsidiary, will promote Hylase to physicians, hospitals and nursing care facilities.
The hyaluronic acid and emollient based gel is a proprietary patented device approved by the FDA pursuant to Section 510 (k).
Hi-Tech president and CEO David Seltzer said with the patented FDA approved device they will expand the portfolio of products and reach additional markets and a growing patient population.